TITLE

The role of recombinant human granulocyte colony-stimulating factor (G-CSF, filgrastim) in the management of pegylated interferon alfa-2b (PEG-IFN) induced neutropenia in patients with chronic hepatitis C (CHC)

AUTHOR(S)
Charuworn, Prista; Ahmed, Ali M; Ahmed, Aijaz
PUB. DATE
September 2003
SOURCE
American Journal of Gastroenterology;Sep2003 Supplement, Vol. 98, pS88
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
An abstract of the article "The Role of Recombinant Human Granulocyte Colony-Stimulating Factor (G-CSF, Filgrastim) in the Management of Pegylated Interferon Alfa-2b (PEG-IFN) Induced Neutropenia in Patients With Chronic Hepatitis C (CHC)," by Prista Charuworn and colleagues is presented.
ACCESSION #
66954324

 

Related Articles

  • Peginterferon-α-2a.  // Reactions Weekly;2/23/2013, Issue 1440, p28 

    The article presents a case study of a 54-year-old man with hepatitis C who developed neutropenia after receiving peginterferon-α-2a.

  • FREQUENCY OF PERIPHERAL BLOOD COUNT ABNORMALITIES IN PATIENTS WITH CHRONIC ACTIVE HEPATITIS C. KHAN, SOFIA; AZIZ, MONA; GHAZANFAR, MASUMA // Biomedica;12/31/2013, Vol. 29 Issue 4, p251 

    Liver disease causes a greater range of hematological changes than does disease in any other organ. Viral hepatitis and its sequel are the important hepatic disorders. Hepatitis C virus (HCV) is considered to be the main etiological factor for chronic liver disease. Present study was done to...

  • Parvovirus B19 Infection in an HIV-Infected Patient with Febrile Pancytopenia and Acute Hepatitis. Alliot, C.; Barrios, M.; Taib, J.; Brunel, M. // European Journal of Clinical Microbiology & Infectious Diseases;Jan2001, Vol. 20 Issue 1, p43 

    The case of a 34-year-old male patient with HIV infection referred for severe febrile pancytopenia is reported. Clinical and laboratory evaluations revealed acute hepatitis B infection and concomitant parvovirus B19 infection. The patient died just before treatment with immune globulin was to be...

  • Role of Hematopoietic Growth Factors as Adjuncts in the Treatment of Chronic Hepatitis C Patients. Danish, Fazal A.; Koul, Salman S.; Subhani, Fazal R.; Rabbani, Ahmed E.; Yasmin, Saeeda // Saudi Journal of Gastroenterology;Jul2008, Vol. 14 Issue 3, p151 

    Drug-induced hematotoxicity is the most common reason for reducing the dose or withdrawing ribavirin (RBV) and interferon (IFN) therapy in chronic hepatitis C, which leads to the elimination of a possible cure for the patient. Traditionally, severe anemia and neutropenia have been considered as...

  • Pharmacogenetics of Efficacy and Safety of HCV Treatment in HCV-HIV Coinfected Patients: Significant Associations with IL28B and SOCS3 Gene Variants. Vidal, Francesc; López-Dupla, Miguel; Laguno, Montserrat; Veloso, Sergi; Mallolas, Josep; Murillas, Javier; Cifuentes, Carmen; Gallart, Lluis; Auguet, Teresa; Sampériz, Gloria; Payeras, Antoni; Hernandez, Pilar; Arnedo, Mireia; Gatell, Josep Ma; Richart, Cristóbal // PLoS Clinical Trials;Nov2012, Vol. 7 Issue 11, p1 

    Background and Aims: This was a safety and efficacy pharmacogenetic study of a previously performed randomized trial which compared the effectiveness of treatment of hepatitis C virus infection with pegylated interferon alpha (pegIFNα) 2a vs. 2b, both with ribavirin, for 48 weeks, in HCV-HIV...

  • Pegylation increases interferon-associated infection risk in hep C?  // Reactions Weekly;10/9/2004, Issue 1022, p4 

    Discusses research being done on whether pegylation increases interferon-associated infection risk in hepatitis C. Reference to a study by Antonini M. G. et al, published in the August 2004 issue of "Antiviral Therapy"; Incidence of infections during treatment with pegylated and standard...

  • Peginterferon-α-2b/ribavirin.  // Reactions Weekly;11/18/2006, Issue 1128, p15 

    The article presents a case report of a female patient who developed Crohn's disease during treatment with peginteferon-α-2b plus ribavirin for the treatment of hepatitis C virus infection. The patient receives peginterferon-α-2b and ribavirin. Due to severe neutropenia, her...

  • Rate of Infectious Complications during Interferon-Based Therapy for Hepatitis C Is Not Related to Neutropenia. Cooper, Curtis L.; Al-Bedwawi, Saif; Lee, Craig; Garber, Gary // Clinical Infectious Diseases;6/15/2006, Vol. 42 Issue 12, p1674 

    The relationship between infectious complications and neutropenia was evaluated in recipients of interferonbased therapy for hepatitis C followed at The Ottawa Hospital Viral Hepatitis Clinic from June 2000 to May 2005. One hundred ninety-two patients received 211 courses of therapy (5707...

  • Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin. Nachnani, Jagdish S.; Rao, Gowtham A.; Bulchandani, Deepti; Pandya, Prashant K.; Alba, Laura M. // Annals of Hematology;Feb2010, Vol. 89 Issue 2, p121 

    Hematological abnormalities including neutropenia, anemia, and thrombocytopenia are commonly seen in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. The aim of this study was to identify factors which would help to predict the development of hematological...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics